SEARCH

SEARCH BY CITATION

References

  • 1
    Berenguer M, Lopez-Labrador X, Wright T. Hepatitis C and liver transplantation. J Hepatol 2001; 35: 666.
  • 2
    Gane E. The natural history and outcome of liver transplantation in hepatitis C virus infected recipients. Liver Transpl 2003; 11: 28.
  • 3
    Garcia-Retortillo M, Forns X, Feliu A, Moitinho E, Costa J, Navasa M. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35: 680.
  • 4
    Schluger LK, Sheiner PA, Thung SN, Lau JY, Min A, Wolf DC. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971.
  • 5
    Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M. HCV related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673.
  • 6
    Berenguer M, Prieto M, Rayon JM, Mora J, Pasor M, Ortiz V. Natural history of clinically compensated HCV-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852.
  • 7
    Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 12: 889.
  • 8
    Prieto M, Berenguer M, Rayon JM, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29: 250.
  • 9
    Wiesner R, Rabkin J, Klintmalm G, et al. A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients. Liver Transpl 2001; 7: 442.
  • 10
    Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8: 40.
  • 11
    Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales F. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975.
  • 12
    Samuel D, Feray C. Recurrence of hepatitis C virus after liver transplantation. J Hepatol 1999; 31(Suppl. 1): 217.
  • 13
    Di Martino V, Saurini F, Samuel D, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997; 26: 1343.
  • 14
    Pelletier SJ, Raymond DP, Crabtree TD, et al. Hepatitis C-induced hepatic allograft injury is associated with a pretransplantation elevated viral replication rate. Hepatology 2000; 32: 418.
  • 15
    Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998; 352: 1426.
  • 16
    Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Heptology 1995; 22: 1084.
  • 17
    Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330: 1160.
  • 18
    Gadano AC, Mosnier JF, Durand F, et al. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59: 1627.
  • 19
    Everson GT, Trotter J, Forman L, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005; 42: 255.
  • 20
    Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696.
  • 21
    Feray C, Caccamo L, Alexander GJ, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619.
  • 22
    Vargas V, Charco R, Castells L, Esteban R, Margarit C. Alpha-interferon for acute hepatitis C in liver transplant patients. Transplant Proc 1995; 27: 1222.
  • 23
    Triantos C, Samonakis D, Stigliano R, Thalheimer U, Patch D, Burroughs A. Liver transplantation and hepatitis C virus: systematic review of antiviral therapy. Transplantation 2005; 79: 261.
  • 24
    Samuel D, Bizollon T, Feray C, et al. Interferon-α 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124: 642.
  • 25
    Castells L, Vargas V, Allende H, et al. Combined treatment with pegylated interferon (α 2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol 2005; 43: 53.
  • 26
    Rodrigues-Luna H, Khatib A, Sharma P, et al. Treatment of recurrent hepatitis C after liver transplantation with combination of pegylated interferon alpha 2b and ribavirin: an open label series. Transplantation 2004; 77: 190.
  • 27
    Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepatol 2004; 40: 669.
  • 28
    Neumann U, Puhl G, Bahra M, et al. Treatment of patients with reccurent hepatitis C after liver transplantation with peginterferon alfa-2b puls ribavirin. Transplantation 2006; 82: 43.
  • 29
    Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452.
  • 30
    Lavezzo B, Franchello A, Smeddile A, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus twelve months course of interferon alpha 2b with ribavirin. J Hepatol 2002; 37: 247.
  • 31
    Ghalib R, Levin C, Stribling R. Treatment of recurrent hepatitis C after liver transplantation with pegylated interferon alfa-2b plus ribavirin. Preliminary analysis [Abstract]. Gastroenterology 2003; 124: A-694.
  • 32
    Fernández I, Meneu JC, Colina F, et al. Clinical and histological efficacy of pegylated interferon and ribavirin therapy of recurrent hepatitis C after liver transplantation. Liver Transpl 2006; 12: 1805.
  • 33
    Chalasani N, Manzarbeitia C, Ferenci P, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289.